eli lilly phase 3 trial retatrutide Remember, it is still in trial. Not yet FDA approved. Expected to be approved in 2027 or early 2028 Retatrutide produces up to 30.3%

Lifelong restriction of dietary branched-chain amino acids has sex-specific benefits for frailty and lifespan in mice

Site rotation prevents lipohypertrophy (fatty lumps under skin), reduces scar tissue formation, and maintains consistent absorption

Where Fridays does stand out: lab work, dietitian access, weekly coaching, and mental health support are all included in every plan tier, with the annual plan landing at $150/month

A key mechanism involves the transforming growth factor-beta (TGF-) signaling pathway

A 6-hour shift in injection time on travel weeks does not meaningfully alter your weekly exposure profile